<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735134</url>
  </required_header>
  <id_info>
    <org_study_id>HYMC-99-18</org_study_id>
    <nct_id>NCT03735134</nct_id>
  </id_info>
  <brief_title>Colchicine in Periprocedural Myocardial Infarction: the Role of Alpha Defensin</brief_title>
  <official_title>Colchicine in Periprocedural Myocardial Infarction: the Role of Alpha Defensin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to study the effect of a loading dose of colchicine on the
      occurrence of periprocedural myocardial infarction (PPMI) in elective percutaneous coronary
      intervention.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of PPMI post elective PCI</measure>
    <time_frame>24 hours post PCI</time_frame>
    <description>Occurrence of PPMI post elective PCI and its relation to defensin levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Traditional inflammatory markers</measure>
    <time_frame>24 hours post PCI</time_frame>
    <description>Determination of traditional inflammatory markers including c-reactive protein, white blood cells and interleukin-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>30 days</time_frame>
    <description>Determining the occurrence of major adverse cardiovascular events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Inflammation</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early colchicine loading dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose 12-24 hours before PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late colchicine loading dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stable coronary artery disease patients who have been assigned to elective PCI and who will be given standard of care treatment plus colchicine loading dose one hour prior to PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine Loading Dose</intervention_name>
    <description>Two milligrams of colchicine will be administrated in addition to the standard of care treatment</description>
    <arm_group_label>Early colchicine loading dose</arm_group_label>
    <arm_group_label>Late colchicine loading dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care treatment prior to elective PCI</intervention_name>
    <description>All medications normally given to patients prior to elective PCI</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized with troponin negative events and scheduled for elective PCI

        Exclusion Criteria:

          -  Significant renal dysfunction

          -  Significant liver dysfunction

          -  Severe left ventricular dysfunction

          -  Severe low weight

          -  Chronic colchicine treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rami Abu Fanne, MD, PhD</last_name>
    <phone>972-50-3573694</phone>
    <email>ramia@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hille Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Rami Abu Fanne, MD, PhD</last_name>
      <phone>972-503573694</phone>
      <email>ramia@hadassah.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 7, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

